Accuracy supported the executive committee in building and modelling its long-term strategic orientations.
The pharmaceutical value chain is experiencing significant market developments including substitution from generics, growth of para-pharmaceutical products, deregulation of retail constraints and market concentration, development of e-commerce, priority placed on prevention services and innovation in logistics solutions. In this fast-moving environment, a global leader asked us to work on its long-term strategy in France.
How we helped
We launched a full portfolio review of our client’s activities (8 business units). For each BU we were able to draw a clear view on its segmented profitability, market dynamics and competitive position.
We also strengthened our quantitative analyses with a set of high-level external interviews along the value chain as well as open business interviews with all the directors of the Group.
The project was organised in two phases:
- First, to undertake a strategic diagnosis and identify main potential orientations;
- Second, for each strategic orientation, to model economic and financial business cases.
We issued clear recommendations on how to turn the business model towards the most attractive segments.
We also delivered fact-based guidance on necessary investments as well as possible divestments from non-core activities.
We supported the executive committee with the necessary management presentation to the Board.